Group 1 - The company, 康方生物, announced a conditional agreement for a placement of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.62% of the existing share capital as of the announcement date [1] - The placement price reflects a discount of about 4.75% compared to the closing price of HKD 157.00 on August 27, 2025 [1] - The estimated total gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion after deducting commissions and related expenses [1] Group 2 - The board was informed that Dr. 夏瑜 and Dr. 李百勇, as sellers, entered into a secondary placement agreement to sell a total of 3 million existing shares, representing about 0.33% of the total issued shares as of the announcement date [2]

假设于本公告日期至一级配售完成的日期间本公司的已发行股本并无变动，一级配售的一级配售股份数 目2355万股占本公告日期本公司已发行股本约2.62%及经发行一级配售股份扩大的已发行股本约 2.56%。配售的一级配售股份最大面值总额将为235.5美元。 配售价为每股一级配售股份149.54港元，较于2025年8月27日(即一级配售协议日期前最后一个完整交易 日)在联交所呈报的收市价每股股份157.00港元折让约4.75%。 本集团为中国的综合药物发现平台。假设所有一级配售股份获悉数配售，则一级配售估计所得款项总额 及净额(扣除配售佣金及其他相关开支及专业费用后)将分别为约35.22亿港元及约34.93亿港元。每股一 级配售股份的净配售价将为约148.32港元。 董事会获告知夏瑜博士(夏博士)及李百勇博士(李博士)(作为卖方)已于2025年8月28日与配售经办人订立 二级配售协议，卖方同意出售或促使出售而配售经办人同意促使买家按二级配售协议所载条款及条件以 配售价购买合共300万股现有股份(即二级配售股份)，占于本公告日期已发行股份总数约0.33%。 智通财经APP讯，康方生物(09926)发布公告，配售代理已有条 ...

Core Insights - The article highlights the top short-selling stocks in the market, indicating significant investor sentiment and potential market movements [1][2][3] Short-Selling Ratios - AIA Group Limited (友邦保险-R) has the highest short-selling ratio at 100.00%, followed by JD Health (京东健康-R) at 93.01% and Anta Sports (安踏体育-R) at 92.84% [1][2] - Other notable mentions include BYD Company Limited (比亚迪股份-R) with a short-selling ratio of 90.97% and Tencent Holdings (腾讯控股-R) at 82.28% [2] Short-Selling Amounts - Meituan (美团-W) leads in short-selling amounts with 3.359 billion, followed by Alibaba Group (阿里巴巴-SW) at 3.259 billion and Tencent Holdings at 2.386 billion [1][3] - Other companies with significant short-selling amounts include Kuaishou Technology (快手-W) at 1.351 billion and SMIC (中芯国际) at 1.308 billion [3] Deviation Values - Tencent Holdings (腾讯控股-R) has the highest deviation value at 44.16%, indicating a significant difference from its average short-selling ratio over the past 30 days [1][3] - AIA Group Limited (友邦保险-R) follows with a deviation value of 36.56%, and China Resources Beer (华润啤酒-R) at 36.35% [1][3]

Group 1 - The core announcement is that 康方生物 (Kangfang Biologics) has entered into a placement agreement with Morgan Stanley to issue 23.55 million shares at a price of HKD 149.54 per share, representing a discount of approximately 4.75% from the closing price of HKD 157.00 on August 27 [1][2] - The placement shares will account for about 2.62% of the company's existing share capital and approximately 2.56% of the enlarged share capital post-placement [1] - The estimated gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion [2] Group 2 - The net proceeds from the placement will be allocated as follows: 80% for global and China innovation R&D pipeline and infrastructure development, 10% for commercialization of existing approved products, and 10% for general corporate purposes [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9926） 根據一般授權配售新股 ...

Key Points - The top three companies with net inflows of southbound funds are Alibaba-W (09988) with 581 million, Kangfang Biotech (09926) with 541 million, and Hong Kong Stock Exchange (00388) with 434 million [1] - The top three companies with net outflows of southbound funds are Yingfu Fund (02800) with -2.396 billion, Xiaomi Group-W (01810) with -1.524 billion, and SMIC (00981) with -845 million [1] - In terms of net inflow ratios, the top three companies are Quan Feng Holdings (02285) at 51.60%, Sen Song International (02155) at 49.91%, and GX China (03040) at 43.94% [1] - The top three companies with the highest net outflow ratios are Yihai International (01579) at -51.63%, Zhou Hei Ya (01458) at -49.54%, and Kangji Medical (09997) at -46.09% [1] Net Inflow Rankings - Alibaba-W (09988) had a net inflow of 581 million, representing a 2.88% increase in closing price to 124.500 [2] - Kangfang Biotech (09926) saw a net inflow of 541 million, with a closing price of 169.500, down 4.18% [2] - Hong Kong Stock Exchange (00388) experienced a net inflow of 434 million, closing at 462.800, up 3.30% [2] - Kuaishou-W (01024) had a net inflow of 428 million, closing at 78.750, up 5.14% [2] - Horizon Robotics-W (09660) recorded a net inflow of 401 million, closing at 7.760, up 1.31% [2] Net Outflow Rankings - Yingfu Fund (02800) had the largest net outflow of -2.396 billion, with a closing price of 26.360, up 2.01% [2] - Xiaomi Group-W (01810) experienced a net outflow of -1.524 billion, closing at 53.500, up 1.81% [2] - SMIC (00981) saw a net outflow of -845 million, with a closing price of 57.800, up 1.58% [2] - CNOOC (00883) had a net outflow of -708 million, closing at 18.830, up 0.53% [2] - Pop Mart (09992) recorded a net outflow of -418 million, closing at 326.600, up 1.94% [2] Net Inflow Ratio Rankings - Quan Feng Holdings (02285) had a net inflow ratio of 51.60%, with a net inflow of 24.33 million, closing at 24.300, up 5.29% [3] - Sen Song International (02155) recorded a net inflow ratio of 49.91%, with a net inflow of 54.68 million, closing at 10.900, up 1.68% [3] - GX China (03040) had a net inflow ratio of 43.94%, with a net inflow of 1.29 million, closing at 37.820, up 2.55% [3] Net Outflow Ratio Rankings - Yihai International (01579) had a net outflow ratio of -51.63%, with a net outflow of -69.47 million, closing at 14.780, up 4.23% [3] - Zhou Hei Ya (01458) recorded a net outflow ratio of -49.54%, with a net outflow of -20.12 million, closing at 2.570, up 2.80% [3] - Kangji Medical (09997) had a net outflow ratio of -46.09%, with a net outflow of -30.83 million, closing at 8.680, up 0.35% [3]

Summary of Key Points from the Conference Call of 康方生物 Company Overview - 康方生物 is advancing in the field of tumor immunotherapy, entering the 2.0 era with products like 卡度尼利 and 伊沃西, while actively exploring the ADC sector and various combination therapies [2][6][8]. Financial Performance - In the first half of 2025, 康方生物 achieved a total revenue of 14.1 billion RMB, with a commercial sales increase of 49% year-on-year [3][49]. - The gross profit from commercial sales was 11.1 billion RMB, a 20% increase from 8.89 billion RMB in the same period last year [50]. - R&D expenses rose by 23% to 7.3 billion RMB, while cash reserves stood at 71.38 billion RMB [50][13]. Clinical and Commercial Achievements - Significant clinical results were reported for AK112, which showed positive overall survival (OS) in EGFR TKI-resistant indications, marking it as the first IO drug to achieve such results globally [4][11]. - Multiple phase III clinical trials for 卡度尼利 have been initiated, covering various cancers including lung, gastric, liver, and cervical cancers [4][5]. - The final analysis of 伊沃西 (Harmony A) demonstrated statistically significant OS results, reinforcing its market position [2][4]. Product Pipeline and Development - 康方生物 has several products in the pipeline, with multiple autoimmune products expected to be approved between late 2024 and early 2025 [2][4]. - The company is focusing on ADC development, with two dual-target ADC products entering clinical stages [4][10]. - The company has independently conducted international multi-center clinical trials for 派安普利, showcasing its capabilities in global registration systems [2][10]. Strategic Direction - 康方生物 aims to enhance its product offerings in tumor immunotherapy and ADC, with plans to combine PD-1 with ADC to improve efficacy and reduce toxicity [6][8]. - The company is expanding its international presence, with clinical data showing consistency between Chinese and global data, indicating the potential for global patient treatment [7][8]. Market Position and Future Outlook - The company has established a strong commercial presence, with its dual antibody products included in the national medical insurance directory, covering over 2,000 hospitals [11][20]. - Future plans include expanding the market for non-tumor drugs and enhancing the commercialization of existing products like AK112 and AK104 [9][20]. - 康方生物 is committed to maintaining a balance between R&D investment and commercial operations, aiming to reduce R&D expenses as a percentage of sales over time [63][62]. Challenges and Considerations - The company reported a loss of 588 million RMB in the first half of 2025, attributed to increased R&D investments and equity investment losses [52][53]. - 毛利率 (gross margin) has decreased due to price adjustments following the inclusion of key products in medical insurance [61][62]. Conclusion - 康方生物 is positioned for significant growth in the biopharmaceutical sector, with a robust pipeline and strategic focus on innovative therapies, while navigating challenges related to financial performance and market dynamics [2][4][8].

Core Viewpoint - Kangfang Biopharma reported a revenue of 1.412 billion yuan for the first half of 2025, marking a year-on-year increase of 37.75%, while the loss expanded to 588 million yuan from 249 million yuan in the same period last year [1][3] Financial Performance - Revenue for the period was 1.412 billion yuan, a 37.75% increase year-on-year [1] - Commercial sales revenue reached 1.402 billion yuan, up 49.20% year-on-year [1] - The company incurred a loss of 588 million yuan, which is an increase from the previous year's loss of 249 million yuan [1][3] Revenue Drivers - The growth in commercial sales revenue was primarily driven by the inclusion of AK104 and AK112 in the national medical insurance since January, leading to increased sales volume [1] - The increase in losses was attributed to a rise in equity investment losses from a partnership with Summit, which increased from 32.6 million yuan to 192 million yuan, as well as higher R&D expenses and stock incentive costs [3] Product Pipeline and Market Position - Kangfang Biopharma has received approval for seven products, including AK104 and AK112, which are key dual antibodies, and has expanded its commercial product range to include metabolic and autoimmune areas [4] - The sales team has grown from over 800 to 1,200 members, covering oncology and specialty drug sectors [4] - The company is focusing on AK112, which has shown promising results in clinical trials for non-small cell lung cancer [5][8] Clinical Development and Strategy - AK112 has achieved significant clinical endpoints in trials, including a statistically significant improvement in progression-free survival (PFS) [8][9] - The company is pursuing a strategy termed "IO2.0+ADC2.0," which aims to integrate dual antibodies with antibody-drug conjugates (ADCs) [12][13] - Kangfang Biopharma's pipeline includes ongoing clinical trials for various indications, with a focus on enhancing the efficacy of existing treatments [12][16]

Group 1 - Southbound funds traded approximately HKD 191.17 billion today, an increase of nearly HKD 43 billion compared to the previous day, accounting for 51.48% of the total turnover of the Hang Seng Index [2] - Despite the decline in Hong Kong stocks, southbound funds significantly increased their positions, with a net purchase of approximately HKD 15.37 billion, including a net inflow of about HKD 9.00 billion from the Shanghai-Hong Kong Stock Connect and HKD 6.37 billion from the Shenzhen-Hong Kong Stock Connect [2] - Major ETFs such as the Tracker Fund of Hong Kong, Hang Seng China Enterprises Index ETF, and Southern Hang Seng Technology ETF saw substantial inflows of HKD 5.55 billion, HKD 3.04 billion, and HKD 0.95 billion respectively [2] Group 2 - Individual stocks with significant net purchases included Alibaba Group (HKD 2.18 billion), Meituan (HKD 1.78 billion), and CanSino Biologics (HKD 0.57 billion) [3] - Stocks with notable net outflows included SMIC (HKD 0.66 billion) and Xiaomi Group (HKD 0.30 billion) [3] Group 3 - Alibaba Group's stock rose by 0.16%, with short-term fund trends remaining unclear, having reduced holdings by 1.54 million shares over the past five days [4] - Meituan's stock fell by 3.08%, but short-term funds accelerated inflows, increasing holdings by 24.10 million shares over the past five days [4] - CanSino Biologics' stock dropped by 7.10%, with short-term fund trends remaining unclear, having reduced holdings by 90,000 shares over the past five days [4] - SMIC's stock rose by 0.09%, with short-term funds primarily flowing in, having increased holdings by 4.22 million shares over the past five days [4] - Xiaomi Group's stock fell by 0.56%, with short-term fund inflows slowing down, having increased holdings by 2.53 million shares over the past five days [4] Group 4 - In the past month, the top active stocks in the Shanghai-Hong Kong Stock Connect included SMIC, Alibaba Group, and Tencent Holdings, with net outflows of HKD 0.59 billion, HKD 1.14 billion, and HKD 0.54 billion respectively [6] - In the Shenzhen-Hong Kong Stock Connect, the top active stocks included SMIC, Alibaba Group, and the Tracker Fund of Hong Kong, with net outflows of HKD 0.72 billion, HKD 1.04 billion, and HKD 2.49 billion respectively [7]

智通财经APP获悉，8月27日港股市场，北水成交净买入153.71亿港元，其中港股通(沪)成交净买入90.05亿港元，港股通(深) 成交净买入63.66亿港元。 北水净买入最多的个股是盈富基金(02800)、恒生中国企业(02828)、阿里巴巴-W(09988)。北水净卖出最多的个股是中芯国际 (00981)、小米集团-W(01810)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 中芯国际 | 31.06亿 | 36.93 乙 | 67.99 亿 | | HK 00981 | | | -5.86 Z | | 阿里巴巴-W | 27.47 乙 | 16.12 Z | 43.60亿 | | HK 09988 | | | +11.35 亿 | | 腾讯控股 | 20.66亿 | 20.12亿 | 40.78亿 | | HK 00700 | | | +5389.26万 | | 恒生中国 ... | 31.25亿 | 8153.80万 | 32.06亿 | | HK 02828 | | | +30.43 亿 | | 盈富基 ...